Together with our genetic and eQTL evidence of the strong association between rs3217869 risk genotype and reduced CCND2 expression, this study identified CCND2 as a plausible causative gene and potential metastatic tumor suppressor underlying genetic predisposition and disease progression to aggressive prostate cancer. This evidence concerns the gene CCND2 and prostate cancer.